"DelRicht Research provides volunteers access to no-cost, advanced treatment options. We empower those who wish to take a more active role in their own health care and experience the next generation of medicine, Today."

During the past decade, DelRicht Research conducted 69 clinical trials. In the 10-year time frame, 69 clinical trials started and 29 clinical trials were completed, i.e. on average, 42% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 29 clinical trials were completed. i.e. 69% of trials that started reached the finish line.

Out of the total clinical trials conducted in "DelRicht Research" #1 sponsor was "Incyte Corporation" with 9 trials, followed by "Pfizer" with 7 trials sponsored, "Urovant Sciences GmbH" with 5 trials sponsored, "Allergan" with 4 trials sponsored and "Eli Lilly and Company" with 4 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "DelRicht Research" #1 collaborator was "Abond CRO Inc." with 1 trials as a collaborator, "Accelovance" with 1 trials as a collaborator, "Alder Biopharmaceuticals, Inc." with 1 trials as a collaborator, "Athenex, Inc." with 1 trials as a collaborator and "BioClinica, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "DelRicht Research" are "Migraine" (11 trials), "Overactive Bladder" (5 trials), "Acne Vulgaris" (4 trials), "Atopic Dermatitis" (4 trials) and "Crohn's Disease" (4 trials). Many other conditions were trialed in "DelRicht Research" in a lesser frequency.

Most popular intervention types in "DelRicht Research" are "Drug" (67 trials), "Other" (5 trials), "Device" (3 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Ruxolitinib cream" (6 trials), "Vehicle" (6 trials), "Rimegepant" (4 trials) and "Vibegron" (4 trials). Other intervention names were less common.

The vast majority of trials in "DelRicht Research" are 60 trials for "All" genders, 5 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "DelRicht Research". undefined are not yet recruiting, 11 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in DelRicht Research, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in DelRicht Research, 2 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".